HHS Proposes Clinical Trial Reform to Restrict Chinese Biotech Sector Participation
The U.S. Department of Health and Human Services on June 23, 2026, proposed a clinical trial reform package aimed at restricting participation by China’s biotech sector in U.S. drug development. According to HHS officials, the initiative, called Operation TrialBlazer, seeks to accelerate domestic trials and counter the shift of early-phase studies to faster jurisdictions like China and Australia, which officials say threatens U.S. leadership and national security.
Operation TrialBlazer, the HHS-wide initiative launched June 23, 2026, sets out a coordinated framework across multiple agencies, including the Food and Drug Administration and the National Institutes of Health, to modernize and accelerate clinical trials in the United States. According to HHS officials, the initiative aims to shorten timelines, reduce regulatory friction, and expand patient enrollment in U.S.-based trials to counter the growing trend of early-phase studies moving to faster jurisdictions such as China and Australia. The department described the effort as an unprecedented push to restore U.S. leadership in clinical research and protect national security interests, explicitly citing China’s rise in the biotech sector as a key driver.
The FDA’s role in Operation TrialBlazer includes piloting an expedited Investigational New Drug (IND) program designed to reduce the time from drug identification to the start of Phase 1 human trials by six to 12 months.
Acting FDA Commissioner Kyle Diamantas said the reforms seek to make conducting early trials in the U.S. more attractive compared to “speedier locales like China and Australia.” The FDA plans to clarify data requirements for IND submissions to eliminate redundant documentation and is proposing a pilot consultation network of U.S. research institutions to assist developers in preparing applications. Additionally, a new rolling submission platform and a dedicated website and call center will be launched to help sponsors, especially small companies, navigate Phase 1 trial requirements.
The NIH is tasked with adapting its clinical trial networks to test new study designs, expand access, and integrate real-world data and advanced analytics. According to agency documents, this includes promoting telehealth, remote monitoring, and artificial intelligence to enable participation by rural and underserved populations, thereby broadening the domestic trial pool. HHS officials emphasized that these reforms are intended to maintain ethical and human-rights protections while improving competitiveness against China’s rapidly modernizing regulatory environment.
The reform package also addresses the issue of patient enrollment incentives. The HHS Office of Inspector General issued a request for information to gather public input on whether federal anti-kickback and civil monetary penalty laws should be modified to allow stipends beyond reimbursement of expenses for trial participants. This measure is part of a broader effort to expand enrollment in U.S.-based trials by helping physicians identify eligible patients and better integrating clinical trials into routine care.
National security concerns about Chinese involvement in U.S. clinical trials have gained prominence in Congress alongside the HHS reforms. In March 2026, Senator Rick Scott sent a letter urging HHS, FDA, and other agencies to review pending and recently approved clinical trial applications involving Chinese state-linked entities and to pause approvals pending security reviews. Scott called for mandatory national-security screening protocols for INDs and trial proposals involving foreign manufacturing, overseas data storage, or sponsors from “foreign adversary” countries such as China. He also requested a comprehensive audit of all active U.S. clinical trials involving Chinese entities or researchers with potential ties to the Chinese Communist Party, citing risks to both national security and patient safety.
The HHS blueprint explicitly responds to China’s rapid approval timelines and large-scale clinical trial capacity, which have attracted U.S. biotech sponsors seeking faster development paths. China’s National Medical Products Administration (NMPA) announced in June 2025 plans to cut waiting periods for certain new-drug clinical trial reviews from 60 days to 30 days for key government-supported therapies, pending public comment. Broader reforms in China aim to overhaul clinical trial management, speed reviews, allow foreign trial data submissions, and expand review staff, strengthening China’s position in global drug development.
These developments have contributed to a pattern in which U.S. biotechs run early-phase trials in China to leverage speed and scale, a trend that U.S. officials cite as a motivator for the Operation TrialBlazer reforms. HHS officials argue that keeping clinical trials and associated patient data inside the United States reduces dependence on Chinese infrastructure and oversight, linking these changes to national security and economic competitiveness. Meanwhile, debate continues over the transmission and storage of U.S. patient data abroad, particularly to entities in China, with some lawmakers calling for limits or prohibitions on sending identifiable patient data to foreign-adversary jurisdictions.
The HHS initiative does not outright ban Chinese participation in U.S. clinical trials but seeks to discourage reliance on foreign trial ecosystems through process reforms and incentives. The department’s coordinated approach aims to balance accelerating domestic drug development with maintaining ethical standards and safeguarding national security amid evolving global competition in the biotech sector.
